P3 Health Partners Inc. (PIII) vs TScan Therapeutics, Inc. (TCRX)
A side-by-side comparison of P3 Health Partners Inc. and TScan Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PIII
P3 Health Partners Inc.
$5.62HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TCRX
TScan Therapeutics, Inc.
$0.28HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PIII vs TCRX
growth of $100 · dividends reinvested · last 5yPIII -98.8% (-58.4%/yr)TCRX -97.2% (-51.0%/yr)TCRX compounded faster over this window
PIII TCRX
PIII vs TCRX: by the numbers
- •PIII is the larger company ($18M vs $17M market cap).
- •Both run net losses; PIII's is the smaller (-6.55% vs -1655.35% net margin).
- •PIII grew revenue faster over the past five years (22.04% vs 3.60% CAGR).
Metrics side by side
Valuation
| Metric | PIII | TCRX |
|---|---|---|
| P/S ratio | 0.01 | 2.37 |
| P/B ratio | N/A | 0.24 |
Profitability
| Metric | PIII | TCRX |
|---|---|---|
| Gross margin | -9.89% | 72.24% |
| Operating margin | -18.53% | -1315.38% |
| Net margin | -6.55% | -1655.35% |
| ROE | -136.36% | -170.55% |
| ROIC | -51.68% | -79.20% |
Growth (annualized)
| Metric | PIII | TCRX |
|---|---|---|
| Revenue CAGR (5Y) | 22.04% | 3.60% |
| Total return CAGR (5Y) | -58.41% | -48.85% |
Frequently asked
- Which has grown faster, PIII or TCRX?
- Over the past five years, PIII grew revenue faster — PIII at a 22.04% CAGR versus TCRX at 3.60%.
- How have PIII and TCRX total returns compared?
- Over the past 5 years, PIII delivered -58.41% and TCRX delivered -48.85% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
P3 Health Partners ROETScan Therapeutics ROEP3 Health Partners operating marginTScan Therapeutics operating marginP3 Health Partners revenue growthTScan Therapeutics revenue growthP3 Health Partners free cash flowTScan Therapeutics free cash flow
P3 Health Partners & TScan Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.